Resources>Antibody Industry Trends>Week 3, October 2024: BARDA Funding

Week 3, October 2024: BARDA Funding

Biointron 2024-10-15 Read time: 2 mins

funding.png

This past week, the Biomedical Advanced Research and Development Authority (BARDA) has provided funding for several antibody-related drug development programs. BARDA is a U.S. government agency within the Department of Health and Human Services (HHS) that funds and supports the development of medical countermeasures to protect against public health threats, such as pandemics, bioterrorism, and other emergencies. 

GigaGen was awarded $135M from BARDA to develop recombinant polyclonal antibody therapies against botulinum neurotoxins (BoNT) and a second biothreat of interest to the agency that will be determined at a later time. This project will support the manufacturing and initial clinical development of a drug product that targets all seven BoNT variants. BoNT, one of the most toxic biological substances, is produced by the bacterium Clostridium botulinum and can cause progressive muscle paralysis from the head to the rest of the body, which can be fatal if left untreated. 

In addition, ModeX Therapeutics, a subsidiary of OPKO Health, also secured substantial funding from BARDA for its COVID-19 and influenza programs. ModeX was awarded a $35M supplement to further develop its multispecific antibody therapies aimed at COVID-19, bringing total awards from BARDA to $110M for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executed. These multispecific antibodies are designed to target multiple viral proteins simultaneously, providing broader protection against evolving strains of the virus. 

Furthermore, BARDA also awarded ModeX an additional $16 million to initiate a program focused on influenza with gene and/or protein delivery modalities. These antibodies have the potential to confer protection in immune-suppressed, cancer and other patients with suboptimal responses to vaccination. 


Subscribe to our Antibody Industry Trends

Recommended Articles

Biointron Insights: Antibody Industry Report (Q1 2025 Insights, Trends & Analysis)

Biointron’s Q1 2025 annual antibody report aims to explore the events and trends……

Mar 31, 2025
Week 2, April 2025: Antibody-Targeted Therapies: A Look at FcRn Inhibitors and Fc Engineering

Just this week, Merida Biosciences emerged from stealth with a $121 million Seri……

Apr 08, 2025
April 2025: Affinity Maturation

Affinity maturation is a fundamental process in the adaptive immune response tha……

Apr 03, 2025
Week 1, April 2025: Emerging Trends in Fc Domain Engineering for Therapeutic Development

The therapeutic potential of monoclonal antibodies (mAbs) has expanded dramatica……

Apr 01, 2025

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.